Evidence map›Paper›PMID 40772226›Full record

ReviewFrontiers in cell and developmental biology2025

Recent advances in aptamer-based biosensing technology for isolation and detection of extracellular vesicles.

Osama Alnaser-Almusa, Mohammed Mahmoud, Mohammed Ilyas, Raghda Adwan, Farah Abul Rub, Noha Alnaser-Almusa, Fayrouz Mustafa, Sana Ahmed, Alaa Alzhrani, Tanveer Ahmad Mir and 3 more

Abstract readReview
In one paragraph

Review in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Osama Alnaser-AlmusaCollege of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
Mohammed MahmoudCollege of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
Mohammed IlyasCollege of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
Raghda AdwanCollege of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
Farah Abul RubCollege of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
Noha Alnaser-AlmusaCollege of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
Fayrouz MustafaCollege of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
Sana AhmedLaboratory of Tissue/Organ Bioengineering & BioMEMS, Organ Transplant Centre of Excellence (TR&I-Dpt), King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
Alaa AlzhraniCollege of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
Tanveer Ahmad MirCollege of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
Mubarak AlabudahashPharmaceutical Analysis Department, Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS), Glasgow, United Kingdom.
Raja ChinnappanCollege of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
Ahmed YaqinuddinCollege of Medicine, Alfaisal University, Riyadh, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since their discovery in the 1970s, extracellular vesicles (EVs) have garnered significant scientific attention due to their involvement in diverse pathological processes, including tumorigenesis. Their unique properties have also piqued interest for various applications such as transporting biomolecules for drug delivery. Researchers have developed numerous isolation and detection methods for EVs, including ultracentrifugation, immunoaffinity capture, and antibody-based biosensors. However, these techniques often suffer from limitations in sensitivity, specificity, and efficiency, hindering their performance and reliability in research and clinical settings. Aptamers are short, single-stranded DNA or RNA molecules created to selectively bind to a specific target and offer a promising alternative to antibodies. These aptamers are identified by a process known as SELEX. By repeatedly selecting and amplifying aptamers with high binding affinity, SELEX can generate aptamers with exceptional specificity and sensitivity. Aptamers can then be incorporated into biosensors, known as aptasensors, for EV isolation, detection, and analysis. Aptasensors offer several advantages over antibody-based methods. They are often more stable, can be produced synthetically at lower cost, and can be easily modified for various applications. Additionally, aptamers can be selected against a wide range of targets, including proteins, nucleic acids, and small molecules, making them versatile tools for EV research. This review discusses various SELEX methods for aptamer detection, the clinical uses of aptamers, and the types of EV analysis methods.

Indexed as

aptamersaptasensorsEVs isolation and detectionexosomesextracellular vesiclesSELEX

Identifiers

PMID40772226
PMCPMC12326547

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.